Lau A H, Chow S S, Ng Y S
Department of Pharmacology, Faculty of Medicine, Basic Medical Sciences Building, Chinese University of Hong Kong, Shatin, New Territories, S.A.R., Hong Kong, People's Republic of China.
Eur J Pharmacol. 2001 Mar 2;414(2-3):295-303. doi: 10.1016/s0014-2999(01)00805-6.
Although direct activation of mast cells by high concentrations (>10(-6) M) of substance P is well established, the effect of sub-micromolar concentrations of the neuropeptide on mast cell activation has not been reported. We hence investigated if substance P would modulate immunologic activation of mast cells by studying the effect of the neuropeptide on anti-rat immunologlobulin E antibody (anti-IgE)-induced histamine release from purified rat peritoneal mast cells. We observed that substance P could dose-dependently potentiate anti-IgE-induced histamine release from rat peritoneal mast cells at concentrations (3x10(-9) M to 3x10(-7) M) which alone induced insignificant or low level of histamine release. While the potentiating effect of substance P was not suppressed by any of the non-peptide tachykinin receptor antagonists CP99994 ((2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine), SR48968 ((S)-N-methyl-N-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl) butyl-benzamide) and SR142801 ((S)-(N)-(1-[3-(1-benzoyl-3(3,4-dichlorophenyl)piperidine-3-yl)propyl]-4-phenylpiperidin-4-yl)-N-methyl-acetamide), it was mimicked by compound 48/80 and suppressed by benzalkonium chloride. Hence, substance P enhanced anti-IgE-induced histamine release through a similar receptor-independent mechanism as the direct mast cell activating action of polybasic compounds. Since high concentrations of substance P required for directly activating mast cells may not be achievable physiologically, the enhancing actions of the neuropeptide on the immunologic activation of mast cells may be more clinically relevant in the pathogenesis of various inflammatory conditions.
尽管高浓度(>10(-6) M)的P物质对肥大细胞的直接激活作用已得到充分证实,但亚微摩尔浓度的神经肽对肥大细胞激活的影响尚未见报道。因此,我们通过研究该神经肽对纯化的大鼠腹膜肥大细胞中抗大鼠免疫球蛋白E抗体(抗IgE)诱导的组胺释放的影响,来探究P物质是否会调节肥大细胞的免疫激活。我们观察到,在单独诱导微不足道或低水平组胺释放的浓度(3×10(-9) M至3×10(-7) M)下,P物质能剂量依赖性地增强抗IgE诱导的大鼠腹膜肥大细胞组胺释放。虽然P物质的增强作用未被任何一种非肽类速激肽受体拮抗剂CP99994((2S,3S)-3-(2-甲氧基苄基氨基)-2-苯基哌啶)、SR48968((S)-N-甲基-N-(4-乙酰氨基-4-苯基哌啶基)-2-(3,4-二氯苯基)丁基-苯甲酰胺)和SR142801((S)-(N)-(1-[3-(1-苯甲酰基-3(3,4-二氯苯基)哌啶-3-基)丙基]-4-苯基哌啶-4-基)-N-甲基-乙酰胺)所抑制,但可被化合物48/80模拟,并被苯扎氯铵抑制。因此,P物质通过与多碱性化合物直接激活肥大细胞的作用类似的非受体依赖性机制增强抗IgE诱导的组胺释放。由于生理上可能无法达到直接激活肥大细胞所需的高浓度P物质,该神经肽对肥大细胞免疫激活的增强作用在各种炎症性疾病的发病机制中可能更具临床相关性。